Table 3.
Performance of clinical risk model and polygenic risk score-enhanced model.
| Group | Clinical risk model |
PRS-enhanced model |
||||
|---|---|---|---|---|---|---|
| AUCa | 95% CI | AUC | 95% CI | p-valueb | ||
| Sex | Men | 0.759 | (0.751, 0.767) | 0.769 | (0.761, 0.778) | 1.614 × 10−8 |
| Women | 0.688 | (0.674, 0.701) | 0.693 | (0.680, 0.707) | 4.254 × 10−3 | |
| Race | European | 0.755 | (0.748, 0.762) | 0.760 | (0.753, 0.768) | 4.371 × 10−8 |
| Non-European | 0.682 | (0.629, 0.735) | 0.686 | (0.635, 0.738) | 0.656 | |
| Age | Age > 50y | 0.751 | (0.743, 0.758) | 0.760 | (0.753, 0.768) | 5.5 × 10−12 |
| Age ⩽ 50y | 0.626 | (0.598, 0.653) | 0.636 | (0.609, 0.663) | 0.028 | |
| All individuals | 0.749 | (0.742, 0.760) | 0.757 | (0.750, 0.765) | 1.799 × 10−11 | |
a
AUC calculated using logistic regression (adjusted the first five principal components) in a validation dataset of 454,486 participants in the UK Biobank of which 5228 had been diagnosed with PAD.
b
Statistical significance of the improvement in AUC after adding PRS was calculated by the Delong test.
AUC, area under the curve; PRS, polygenic risk score.